Effect of Intrathecal Magnesium Sulfate Versus Intravenous Magnesium Sulfate on Postoperative Pain After Abdominal Hysterectomy

Launched by ASSIUT UNIVERSITY · Apr 12, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how effective two different ways of giving magnesium sulfate are for managing pain after a total abdominal hysterectomy, which is a surgery to remove the uterus. The researchers want to see if using magnesium sulfate through an injection into the spine (intrathecal) is better than giving it through an IV (intravenous) when combined with another medication called bupivacaine. They will look at how long pain relief lasts, how stable patients' blood pressure and heart rate are after surgery, and if there are any complications.

To participate in this study, women aged 40 to 65 who are scheduled for an abdominal hysterectomy and are classified as having low to moderate health risks (ASA status I or II) may be eligible. However, those with a very high body weight, certain health conditions affecting the heart, kidneys, or liver, or who have had previous abdominal surgeries (except for cesarean sections) will not be eligible. Participants can expect to receive careful monitoring during the trial and to provide valuable information that could help improve pain management after surgery in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Patients between 40-65 years old
• • Patients with ASA clinical status I/II
• • Patients eligible for abdominal hysterectomy
• • Oncological surgery
• Exclusion Criteria:
• • Body mass index (BMI) ≥ 40/kg / m2
• • Previous abdominal surgery (except cesarean section)
• • Severe cardiovascular, renal, and hepatic dysfunction
• • Contraindications to spinal anesthesia
• • Neuromuscular diseases
• • Inappropriate for spinal anesthesia
• • Patient refusal